classification and as a potential target for therapy. We, therefore, performed a systematic analysis of TERT promoter mutations in 1,515 tumors of the human nervous system and its coverings including 373 pediatric and 1,142 adult patients. We detected a total of 327 mutations. TERT promoter mutations were exceedingly rare in tumors typically encountered in pediatric patients. In entities typically encountered in adult patients TERT promoter mutations were strongly associated with older age (p < 0.0001). Highest mutation frequencies were detected in gliosarcomas (81 %), oligodendrogliomas (78 %), oligoastrocytomas Abstract Hot spot mutations in the promoter region of telomerase reverse transcriptase (TERT) have recently been described in several human tumor entities. These mutations result in an upregulation of the telomerase complex activity and thus constitute a relevant mechanism for immortalization of tumor cells. Knowledge of the TERT promoter status in tumors is likely to be of interest for molecular (58 %), primary glioblastomas (54 %), and solitary fibrous tumors (50 %). related to other molecular alterations, TERT promoter mutations were strongly associated with 1p/19q loss (p < 0.0001), but inversely associated with loss of ATrX expression (p < 0.0001) and IDH1/IDH2 mutations (p < 0.0001). TERT promoter mutations are typically found in adult patients and occur in a highly tumor typeassociated distribution.
Introduction
Telomeres are composed of repetitive nucleotide sequences which together with associated proteins constitute important structural elements at the physical ends of chromosomes. Telomere length shortens with each cell division, and this degradation eventually leads to replicative senescence. Immortalization is a crucial bottleneck to be passed in the evolution of a cancer cell, and the ability to maintain telomere length is therefore a typical feature of neoplasia. Telomeres are extended by the protein complex telomerase, in which the enzyme telomerase reverse transcriptase (TerT) plays a pivotal role [33] . Previous studies have shown a strong expression of TerT in the vast majority of human cancers [29] , although the underlying mechanisms of TerT upregulation were largely unknown. recently, several alterations within the TERT gene have been detected in human tumors. Single nucleotide polymorphisms in the TERT gene have been associated with telomere length and have been associated with risk of breast and ovarian cancer [3] . Also the methylation status of distinct Cpg sites in the TERT promoter has been associated with TerT expression, tumor progression, and poor prognosis in pediatric nervous system tumors [5] . The most frequent alteration in the TERT gene, somatic promoter mutation, has been described in melanoma [9, 12, 13] , primary nervous system tumors [2, 14, 17, 23, 30] , thyroid [15, 16] , hepatocellular carcinomas [21] , and bladder [17] as well as many other tumor types [14, 30] . Two essentially mutually exclusive hot spot mutations in the promoter region have been reported: a cytosine-to-thymine transition at chromosome 5 base position 1,295,228 (C228T) or less frequently at base position 1,295,250 (C250T). Both changes create a new binding site for e-twenty-six (eTS) transcription factors, resulting in an up to fivefold increased induction of the TERT gene [13] .
Another mechanism relevant for maintaining telomere length is alternate lengthening of telomeres (AlT) [4] , which is a homologous recombination-dependent process typically associated with mutations in the chromatin remodeling genes α-thalassemia/mental-retardation-syndrome-X-linked (ATRX) and death-associated protein 6 (DAXX) [11] . AlT has been demonstrated in gliomas and other tumors [7, 8] . However, TERT promoter mutations appear to be the single most frequently occurring mechanism to affect telomere length.
So far, the TERT promoter status has been published for 1,507 nervous system tumors [2, 14, 17, 23, 30] . The vast majority of these tumors were from adult patients and 843/1,507 tumors have been diagnosed as glioblastoma (Supplementary Table 1 ). In order to provide a comprehensive overview of the frequency of TERT promoter mutations we analyzed 1,515 nervous system tumors covering a wide range of diagnoses from 373 pediatric and 1,142 adult patients [19] .
Materials and methods

Tissue samples
Tumor tissues for DNA extraction were obtained from the archives of the Institutes and Departments of Neuropathology at the University Hospitals Münster, Hannover, Frankfurt, Tübingen, Magdeburg, and Heidelberg (germany). research use of tissues and anonymization of data were in accordance with local ethical approvals. Tumors from patients younger than 18 years of age were termed pediatric and tumors from patients aged 18 or older were termed adult. Diagnosis, age, and TERT promoter mutation status for each patient are given in Supplementary Table 2. Further molecular data are summarized for astrocytic tumors,  oligodendroglial tumors, and medulloblastomas in Supplementary Tables 3-5. 1 3
DNA-based methods
Amplicons of 163 bp spanning the hot spot mutations at positions 1,295,228 and 1,295,250 on chromosome 5 were amplified using 20 ng each of the forward primer 5′CAgCgCTgCCTgAAACTC and the reverse primer 5′gTCCTgCCCCTTCACCTT. Primer design was based on accession number NC_000005.9. 80 ng of DNA and AccuPrime™ gC-rich DNA polymerase kit (life Technologies, Darmstadt, germany) were employed. PCr was performed in a total volume of 25 μl, and included initial denaturation at 95 °C for 180 s, followed by 35 cycles with denaturation at 95 °C for 30 s, annealing at 62 °C for 25 s, and extension at 72 °C for 30 s. The amplification product was purified and cleaned up by agarose gel electrophoresis. Subsequently the 163-bp products were gel-extracted with the NucleoSpin ® gel and PCr clean-up kit (Macherey-Nagel, Düren, germany) according to the manufacturers' protocol. Two microliters of the purified amplification product was submitted to bidirectional sequencing using the BigDye terminator v3.1 sequencing kit (Applied Biosystems, Foster City, CA, USA). Sequences were determined using an ABI 3500 genetic analyzer (Applied Biosystems) and the Sequence Pilot version 4.0.1 (JSIMedisys, Kippenheim, germany) software.
Determination of hot spot mutations in BRAF and IDH1/2, and testing for 1p/19q lOH were carried out as previously described [10, 25, 26] .
ATrX immunohistochemistry
ATrX staining was performed as previously described [32] . In brief, ATrX polyclonal rabbit antibody (dilution 1:400, product code HPA001906, Sigma-Aldrich, St. louis, MO, USA) was used. Staining was performed using an automated immunostainer (Benchmark Ultra, Ventana, Tucson, AZ, USA) and standard protocols including pretreatment using Cell Conditioning 1 buffer (Ventana) for 52 min and standard Ventana signal amplification. ATrX data have been reported in part previously [32] .
Statistics
Fisher's exact test was used to examine associations between nominal variables. Student's t test was used to examine the association between nominal variables and age.
Results and discussion
This study presents a comprehensive overview of TERT promoter mutations in tumors of the nervous system and its coverings. A total of 1,515 tumors were tested and 327 TERT promoter mutations were found. The C228T mutation was detected 257 times, making it more frequent than the C250T mutation seen in 68 cases. Two further mutation variants were sporadically observed: a pediatric glioblastoma with C228A mutation and a pleomorphic xanthoastrocytoma with C249T mutation. A summary of the pediatric and adult tumors and corresponding mutation rates for the TERT promoter are given in Table 1 . Although TERT promoter mutations overall were very frequent, we also detected significant differences between distinct tumor entities.
Astrocytic tumors
TERT promoter mutations were not detected in 111 pilocytic astrocytomas WHO grade I. likewise, the rare variants of subependymal giant cell astrocytoma WHO grade I and pilomyxoid astrocytoma WHO grade II did not show this alteration. Pleomorphic xanthoastrocytomas WHO grade II (PXA II) had a low frequency of mutations with a single case out of 25 tested tumors bearing a unique C249T mutation. Pleomorphic xanthoastrocytomas with anaplastic features (PXA waf) exhibited TERT promoter mutations in 3/13 instances. All three patients were of older age. TERT promoter hot spot mutations create a new binding site for eTS transcription factors, which are partly regulated by the mitogen-activated protein kinase (MAP kinase) signaling pathway, in which BrAF acts as an upstream signaling kinase [31] . Furthermore, BRAF V600e is a hallmark mutation in PXAs [26] and leads to aberrant MAPK signaling [6] . Coincidental occurrence of BRAF V600e and TERT promoter mutations has been described in thyroid cancers [15, 16] . However, in PXAs there was no association between TERT promoter and BRAF V600e mutation (p = 0.6; Supplementary Fig. 1a ).
Diffuse astrocytomas WHO grade II exhibited TERT promoter mutations in 8/25 cases and showed a strong inverse association with the presence of IDH1/IDH2 mutations (p < 0.05; Supplementary Fig. 1b ) [14] . Similar observations were made for anaplastic astrocytoma WHO grade III with TERT promoter mutations in 30/118 cases, also inversely associated with IDH1/IDH2 (p < 0.0001; Supplementary Fig. 1c ). ATrX alterations have been shown to closely overlap with IDH1/IDH2 and TP53 mutations in astrocytoma [18, 32] . likewise, we observed an inverse association between loss of ATrX expression and TERT promoter mutations (p < 0.05; Supplementary Fig. 1d ). Primary glioblastoma in adults exhibited a high incidence of TERT promoter mutations (79/147, 54 %) whereas only 1/20 secondary glioblastomas had a mutation. For primary glioblastoma this matches previous observations and supports the inverse association of TERT promoter and IDH mutations. Our mutation frequency of 5 % in secondary glioblastomas is lower than the 28 % previously observed [23] , although the number of secondary glioblastomas in our series is rather small. The observation of TERT mutations in 33 % of diffuse astrocytomas and 28 % of anaplastic astrocytomas would also suggest a higher frequency of this alteration in secondary glioblastomas than identified in our series. The rare and controversially discussed glioblastoma with oligodendroglial differentiation exhibited TERT promoter mutation in 4/6 cases. Because TERT promoter mutations are frequent in primary glioblastoma and anaplastic oligodendroglioma, this parameter most likely will not be helpful in the debate on the origins of glioblastoma with oligodendroglial differentiation. giant cell glioblastomas were mutated in 6/17 cases. This variant has been shown to be strongly associated with TP53 mutations [20, 24] . gliosarcomas carried TERT promoter mutations in 21/26 instances, the highest mutation prevalence in our series. Among gliomatoses 7/10 tumors harbored the mutation. In contrast to the situation in adult patients, TERT promoter hot spot mutations were not present in pediatric primary glioblastomas except one case with a unique C228A mutation. Constitutional DNA from this patient was not available. However, single somatic C228A mutations have already been described in one ovarian carcinoma and in two urothelial carcinomas [14] . In contrast to the C228T and C250T changes, the C228A alteration does not create the new binding site for eTS transcription factors. However, an effect of this alteration on binding of other transcription factors cannot be excluded. Our pediatric glioblastoma multiforme (gBM) with C228A mutation was wild type for H3F3A, which has frequently been mutated in pediatric glioblastomas and typically associated with ATRX mutation and AlT characteristics [27] . ATRX mutations frequently occur in pediatric gBMs [27] and, in adult glioma, are mutually exclusive with TERT promoter mutation [2] . We detected ATrX mutation/loss of expression in 3/11 pediatric glioblastomas (Fig. 1) . Current data regarding the association of AlT status and ATrX loss in adult gBMs are controversial. Whereas one series detected the presence of AlT in approximately 25 % [1] , two other series detected AlT in less than 14 % [22] and 7 % [18] of adult gBM. Also, one series did not find a difference in frequency of AlT between adult and pediatric gBM [1] , whereas another series found this alteration three times more frequent in pediatric glioblastoma [22] . Whereas two studies found a tight correlation between AlT phenotype and loss of ATrX expression [1, 22] , another did not [18] . More comprehensive and histopathologically clearly defined series of tumors need to be examined to resolve these discrepancies.
Oligodendroglial tumors
TERT promoter mutations were found in 29/37 oligodendrogliomas WHO grade II and in 29/38 anaplastic oligodendrogliomas WHO grade III. Oligoastrocytomas WHO grade II presented with TERT promoter mutations in 11/19 instances, whereas the incidence in anaplastic oligoastrocytomas WHO grade III was 45/86. Therefore, oligoastrocytomas had a lower prevalence of TERT promoter mutations than pure oligodendrogliomas. However, there was no increase of mutation frequency with increasing malignancy grade in oligodendroglial tumors. TERT mutations were frequent in oligodendroglial tumor entities, regardless of the WHO grade. Previous studies have highlighted the strong association of 1p/19q loss and TERT promoter mutations [2, 14] . This is consistent with our series, in which oligodendroglial tumors with a combined 1p/19q loss were significantly more frequently TERT promoter mutated (49/56; 88 %) compared with oligodendroglial tumors with 1p/19q retention (8/22; 36 %) (p < 0.0001; Supplementary Fig. 1e ). loss of ATrX expression was observed in 13/55 oligodendroglial tumors and inversely associated with TERT promoter mutations. Vice versa 28/42 cases with retained ATrX expression were TERT promoter mutated (p < 0.0001; Supplementary Fig. 1f ). Ten of 14 ATrXexpressing cases with TERT promoter wild-type status were oligoastrocytomas.
ependymal tumors
TERT promoter mutations were found in 0/12 subependymomas WHO grade I and 0/14 myxopapillary ependymomas WHO grade I. Five of 73 ependymomas WHO grade II and 2/46 anaplastic ependymomas WHO grade III had the TERT promoter mutation. All TERT mutations in ependymomas occurred in adult patients with these seven patients being aged between 55 and 67 years. Thus, TERT promoter mutations were absent in all pediatric ependymomas and in two subgroups of ependymoma graded WHO I, i.e., subependymoma and myxopapillary ependymoma. Adult patients with WHO grade II and WHO grade III anaplastic ependymoma younger than 50 years did not carry TERT mutations, whereas more than 25 % of the ependymoma patients 50 years or older had a TERT promoter mutation.
embryonal tumors
In concordance with previous data [14] we detected TERT promoter mutations in 17/91 medulloblastomas. Fifteen of the 17 patients with TERT mutations in medulloblastoma were of adult age and 15 of the mutated tumors were allotted to the SHH group of medulloblastoma. Thus, although rare in pediatric medulloblastomas (3 %), TERT mutations were very frequent in adult medulloblastomas (65 %) and particularly in adult SHH subgroup tumors (13/13, 100 %). In this patient set, we observed a strong prevalence of the C228T mutation. TERT promoter mutations were absent or seen only at very low frequency in all other embryonal tumor entities.
Meningeal tumors
Previous investigations have found no TERT promoter mutations in meningiomas [14] . Accordingly we detected no TERT promoter mutations in 91 meningiomas WHO grade I of different subtypes. However, in atypical (WHO grade II) and anaplastic/rhabdoid meningiomas (WHO grade III) we detected mutations in 2/49 and 6/37 instances, respectively. Thus, the frequency of TERT promoter mutations increased with higher malignancy. Hemangiopericytomas (HPC) and solitary fibrous tumors (SFT) have recently been shown to share the recurrent NAB2-STAT6 fusion that leads to a strong nuclear translocation of STAT6 [28] . This molecular hallmark alteration now allows for a sharp separation of HPCs/SFTs from atypical and anaplastic meningiomas. Since SFT/HPC both shared this gene fusion, we expected no pronounced difference in TERT promoter mutation frequency between the two entities. In a previously analyzed smaller series of SFT/HPC 2 of 10 cases showed TERT promoter mutations [14] . Interestingly, we detected mutations in only 3/27 HPCs but in 8/16 SFTs. This difference in TERT promoter mutation frequency between HPC and SFT is unexplained. No TERT promoter mutation was observed in 13 hemangioblastomas WHO grade I.
Other tumors of the nervous system
The other tumor groups as defined by WHO, including choroid plexus tumors, neuronal and mixed neuronalglial tumors, tumors of the pineal region, tumors of the cranial and paraspinal nerves, tumors of the hematopoietic system with primary lymphomas and histiocytic tumors, germ cell tumors, and tumors of the sellar region exhibited TERT promoter mutations in only a few single instances (Table 1) . For several of the rare entities, however, only low numbers of tumors were available for analysis.
TERT mutations in adult and pediatric patients with nervous system tumors A clear accumulation of TERT promoter mutations was seen in adult astrocytomas, glioblastomas, and oligodendroglial tumors. Also the less frequent TERT promoter mutations in ependymomas exclusively occurred in adult patients of older age. A further group of special interest is adult patients with medulloblastoma who, in contrast to their pediatric counterparts, exhibited a high incidence of TERT mutations. In addition, there also seems to be some association of TERT mutations with higher grades of malignancy in meningioma.
In contrast to adults, pediatric patients very rarely exhibited TERT promoter mutations. Overall only 7 TERT promoter mutations were observed in 373 pediatric tumors. This is of special interest in the case of tumors which occur across ages, e.g., medulloblastoma, glioblastoma, and ependymoma, where TERT mutations were quite frequently observed in adult patients but not in children. Pilocytic astrocytoma WHO grade I, the most frequent pediatric nervous system tumor, also did not exhibit TERT promoter mutations.
We analyzed the association of TERT promoter status with age for those entities with high TERT promoter mutation frequencies and with high numbers of patients included. We pooled astrocytomas WHO grade II and III, oligoastrocytomas WHO grade II and III, and oligodendrogliomas WHO grade II and III because TERT promoter mutation frequencies were independent of grade within these entities. TERT promoter mutations were strongly confined to older age in glioblastomas (p < 0.0001), astrocytomas (p < 0.0001), oligoastrocytomas (p < 0.05), oligodendrogliomas (p < 0.05), and medulloblastomas (p < 0.0001) (Fig. 2a-f) .
Our findings support the notion that immortalization of tumor cells in pediatric nervous system tumor patients generally is not achieved by TERT promoter mutationmediated activation of telomerase. Other mechanisms of telomerase activation might very well be of importance in this age group as demonstrated by a recent publication associating the methylation status of TERT with prognosis in pediatric nervous system tumors [5] , and by the finding of AlT in a high proportion of pediatric glioblastomas [27] .
Conclusion
TERT promoter mutations predominantly occur in glial tumors of adult patients. They are most frequent in astrocytic and oligodendroglial tumors of WHO grade II and higher. In contrast, pediatric nervous system tumor patients rarely have TERT promoter mutations. In those instances where TERT mutations were found in typical pediatric tumors, the patients were of older age. 
